Creative Medical issues letter to shareholders

Creative Medical (CELZ) Technology issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. “2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company’s history, we have evolved from proof-of-concept to clinical trials in support of our mission to develop breakthrough regenerative stem cell therapies across multiple indications… Unlike conventional biotech firms built around a single product, Creative Medical’s diversified platform strategy provides multiple shots on goal across vast therapeutic frontiers… Creative Medical is advancing two pivotal FDA-cleared clinical programs that target multi-billion-dollar markets and represent major potential near-term catalysts. CELZ-201-DDT… This randomized, placebo-controlled Phase I/II trial has received FDA Fast Track Designation and is designed to validate AlloStem’s potential to regenerate and remodel disc tissue. Topline results are anticipated in the first half of 2026. CELZ-201: Focused on new-onset Type 1 Diabetes, a condition with a global treatment market estimated at $35 billion annually. This study targets the autoimmune root cause of the disease rather than symptom management, a radical shift in treatment philosophy. Recruitment is accelerating across multiple sites, with early data expected in 2026.”